{"database":"ecrin-mdr-crc","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":0,"searchCount":0},"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Stomach Diseases","Colorectal Cancer","Colorectal Neoplasms","Stomach Disease","Neoplasms"],"disease":["Stomach Diseases","Colorectal Cancer","Colorectal Neoplasms","Stomach Disease","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2136222"],"location":["Taiwan"],"study_start_month":["7"],"keyword":["IFOBT","One-day sample","Helicobacter pylori stool antigen","Two-day sample"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"citation_count":["0"],"additional_accession":[]},"is_claimable":false,"name":"Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing","description":"1. The abundant results from this trial will be helpful for assessing the feasibility of increasing stool sampling and shortening screening interval in population setting for lower and upper gastrointestinal tract lesions, their long-term effects, and the respective cost-effectiveness.\n2. The study will evaluate the value of population-based screen and treatment for H. pylori infection when the HPSA is combined with the FIT.","dates":{"creation":"2012-07-15"},"accession":"2136222","cross_references":{"ClinicalTrials___gov":["NCT01741363"]}}